Rheumatoid Arthritis
General Overview
General Overview
- Definition
- Inflammatory arthritis involving 3+ joints
- Duration >6w
- Positive RF and/or anti-CCP
- Elevated CRP/ESR
- No evidence of other diseases (eg. psoriatic arthritis, viral polyarthritis, gout/pseudogout, SLE)
Risk
Risk
- Age
- Female
- Family history
- Smoking (both current and prior)
- Early menarche (<10yo)
- Very irregular menstrual periods
- Nulliparous
History
History
- Duration morning stiffness >30mins
- Joint pain location, swelling, tender
- Function, ADLs
- Extrarticular
- Anemia
- Subcutaneous (rheumatoid) nodules
- Pleuropericarditis
- Neuropathy
- Episcleritis/scleritis
- Splenomegaly
- Sjögren's syndrome
- Vasculitis
- Renal disease
- Rule out other causes
- Spondyloarthropathy - Psoriasis, IBD, prominent back involvement
- SLE - Malar/discoid rash, oral ulcers, anti-dsDNA, anti-Sm
- Viral - Less than 6 weeks of symptoms
- Crystal arthropathy - Recurrent self-limited episodes
- Fibromyalgia (can coexist with RA)
Physical exam
Physical exam
- Joint exam
- Limited joint ROM
- Synovial hypertrophy/thickening, effusion, inflammation, tenderness
- Classically involving MCP, PIP, thumb IP, wrists, MTP
- Extraarticular disease manifestations (as above)
- Skin (rheumatoid nodules)
- Lung
- Cardiac
- Eye
Investigations
Investigations
- Labs
- ESR, CRP
- RF
- Anti-citrullinated protein or peptide antibodies (Anti-CCP)
- Antinuclear antibodies (ANA)
- Consider CBC (anemia) , liver, kidney, uric acid, UA
- Imaging (joint erosions)
- Bilateral radiographs of hands, wrists, feet
- May consider MRI/ultrasound
- May consider arthrocentesis to rule out other causes
- May consider viral testing if short history and seronegative for anti-CCP and RF
- eg. Human parovirus B19, HBV, HCV, Lyme
Treatment
Treatment
- Patient education
- Smoking cessation
- Psychosocial interventions
- Guided exercise program
- PT/OT
- Assess CV risk factors (highest cause of mortality)
- Rapid referral to rheumatology
- NSAIDs, glucocorticoids for bridging to DMARDs, flares
- DMARDs as soon as diagnosis of RA made (eg. within 3mo)
- Methotrexate is first-line (other DMARDs include sulfasalazine, leflunomide, hydroxychloroquine, biologics)
- Screening for latent TB, HepB/C as needed
- Eye exam prior to hydroxychloroquine
- Frequent follow-up to assess disease activity q1-3 months (treat-to-target: sustained remission or low disease activity)
- Monitor for complication of RA and treatment
- Depression
- Infection
- Malignancy (lymphoma, lung, skin)
References:
- EULAR 2016. http://ard.bmj.com/content/76/6/960
- ACR 2015. https://www.rheumatology.org/Portals/0/Files/ACR%202015%20RA%20Guideline.pdf
- AAFP 2015. https://www.aafp.org/afp/2015/0701/p35.html
- AAFP 2011. https://www.aafp.org/afp/2011/1201/p1245.html
- CRA 2011/2012. https://rheum.ca/en/publications/cra_ra_guidelines
- RACGP 2009. https://www.racgp.org.au/your-practice/guidelines/musculoskeletal/rheumatoidarthritis/
- MD CME. Getting a GRIP on Arthritis. https://www.mdcme.ca/grip/